Short term pressure on Intuitive Surgical stock

Intuitive Surgical (ISRG) has been under clear pressure recently, with the stock down 2.4% on the day, 7.9% over the past week, about 12% over the past month, and roughly 19.7% over the past 3 months.

Over a longer horizon, the stock is down about 28.4% year to date and roughly 27.1% over the past year, even though its 3 year and 5 year total returns are positive at about 27.4% and 44.8% respectively.

With the share price at $402.30 and the 1 year total shareholder return down 27.1%, recent weakness suggests fading momentum despite positive 3 year and 5 year total shareholder returns.

If Intuitive Surgical’s pullback has you reassessing healthcare exposure, it could be a good moment to scan other opportunities in the sector using our 39 healthcare AI stocks.

With Intuitive Surgical stock under pressure despite positive multi year returns, current revenue and net income growth, and a small intrinsic discount, you have to ask: is there real value on the table, or is future growth already priced in?

Most Popular Narrative: 24.4% Undervalued

Tokyo’s narrative for Intuitive Surgical pegs fair value at $532.46, against the last close of $402.30, framing the recent share price pullback very differently from the market.

Over the next 5 years I calculate with (actual values from 18.01.26, price/shr at 533 USD): Revenue Growth p.a.: 12% (Currently at 14.7%). We saw the peak of revenue growth with nearly 15%. Now even 12% is ambitious, but with the subscription-like revenues from spare parts and software licences, based on a still growing base of installed systems, this is realistic. Profit Margin: 30% (currently at 28.6%) because spare parts in general have more margin than system sales, and the sales from spare parts are still growing. Future PE: 50 (currently at 69). High PEs are typical for fast growers, but over time the PE will go down. I see 50 for the next 5 years and in 10 years it could come down to 40.

Curious what turns a high growth, high multiple surgical robotics stock into a 24.4% discount story? The narrative leans on recurring revenue, margin expansion, and a future valuation multiple more usually associated with premium growth companies. The full breakdown shows how those pieces connect to reach a fair value above $500.

Result: Fair Value of $532.46 (UNDERVALUED)

However, this 24.4% discount story could be challenged if procedure volumes soften or if new competing robotic platforms curb Intuitive Surgical’s pricing power and recurring revenue potential.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another Take: High Multiple, Tight Margin For Error

Tokyo’s user narrative leans on a 24.4% upside to fair value, but the market’s current P/E of 47.8x tells a different story. That is roughly double the US Medical Equipment industry at 24.2x and well above peers at 24.6x. A fair ratio of 31.3x suggests less room for disappointment if growth cools.

For investors weighing this richer P/E against the underpriced cash flow view, the key question is whether Intuitive Surgical has earned a premium that will last, or whether sentiment can shift faster than fundamentals.

Next Steps

With sentiment clearly split between premium pricing and perceived undervaluation, it makes sense to move quickly and test the numbers yourself. Start by checking the 4 key rewards.

Looking for more investment ideas?

Intuitive Surgical might be front of mind today, but your next strong idea could be sitting elsewhere. Use the screeners below so you do not miss it.

• Target steadier opportunities by focusing on companies with resilient finances using our 63 resilient stocks with low risk scores.
• Hunt for strong businesses priced below what their fundamentals suggest with the 46 high quality undervalued stocks.
• Spot quality companies that the market has not fully noticed yet through the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.